Candel Therapeutics (NASDAQ:CADL) CTO Sells $84,000.00 in Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 7,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the completion of the sale, the chief technology officer directly owned 76,865 shares in the company, valued at approximately $922,380. This represents a 8.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Seshu Tyagarajan also recently made the following trade(s):

• On Monday, June 29th, Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock. The stock was sold at an average price of $10.02, for a total value of $70,140.00.

Candel Therapeutics Stock Performance

Shares of Candel Therapeutics stock opened at $13.13 on Friday. Candel Therapeutics, Inc. has a 1 year low of $4.35 and a 1 year high of $13.82. The firm’s 50-day moving average is $10.10 and its 200 day moving average is $7.63. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -9.31 and a beta of -0.51. The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28). Sell-side analysts anticipate that Candel Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Candel Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets grew its holdings in shares of Candel Therapeutics by 128.2% in the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after acquiring an additional 4,439 shares during the period. Tower Research Capital LLC TRC boosted its position in Candel Therapeutics by 361.7% in the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after purchasing an additional 7,527 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Candel Therapeutics during the 4th quarter valued at about $51,000. ProShare Advisors LLC bought a new stake in shares of Candel Therapeutics during the 4th quarter valued at about $59,000. Finally, Invesco Ltd. purchased a new stake in shares of Candel Therapeutics during the 1st quarter valued at about $59,000. 13.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have commented on CADL shares. Stifel Nicolaus began coverage on Candel Therapeutics in a research note on Monday, July 13th. They set a “buy” rating and a $22.00 target price on the stock. UBS Group reaffirmed a “buy” rating on shares of Candel Therapeutics in a report on Monday. Wall Street Zen downgraded Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Finally, Bank of America upped their target price on shares of Candel Therapeutics from $9.00 to $12.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Candel Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $19.29.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.